Sab Biotherapeutics, INC Form 4 insider transactions

Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc., reported a transaction involving the withholding of shares for tax purposes.

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, disposed of 988 common shares to cover tax obligations related to RSU vesting.

SAB Biotherapeutics' President and Director, Eddie Joe Sullivan, was granted 3 million stock options with an exercise price of $4.45, vesting over four years.

SAB Biotherapeutics CEO Samuel J. Reich was granted 4.8 million stock options with an exercise price of $4.45, vesting over four years.

SAB Biotherapeutics' Chief Operating Officer, Christoph Bausch, was granted 1.8 million stock options with an exercise price of $4.45, vesting over four years.

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, was granted 2.4 million stock options with an exercise price of $4.45 per share.

SAB Biotherapeutics' Chief Financial Officer, Lucy To, was granted 2.4 million stock options with an exercise price of $4.45, vesting over four years.

SAB Biotherapeutics director Rita Jain was granted 240,000 stock options with an exercise price of $3.74, vesting over three years.

SAB Biotherapeutics Director David Zaccardelli received an inaugural grant of 240,000 stock options with a $3.74 exercise price, vesting over three years.

SAB Biotherapeutics director Jay S. Skyler was granted 150,000 stock options with an exercise price of $3.99 as part of his 2025 annual compensation.

SAB Biotherapeutics director William James Polvino received an annual grant of 150,000 stock options with an exercise price of $3.99, vesting over two years.

SAB Biotherapeutics Director Erick Lucera was granted 150,000 stock options as part of his 2025 annual compensation, vesting over two years.

SAB Biotherapeutics Director Helen K. Ellias received an annual grant of 150,000 stock options with an exercise price of $3.99.

SAB Biotherapeutics director Scott Giberson received an annual grant of 150,000 stock options with an exercise price of $3.99, vesting over two years.

SAB Biotherapeutics Director David Link received an annual grant of 150,000 stock options with an exercise price of $3.99, vesting over two years.

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, reported a transaction involving shares withheld for tax obligations related to restricted stock unit vesting.

SAB Biotherapeutics director Andrew Moin's affiliated entity converted 17,400 shares of Series B Preferred Stock into 1.74 million common shares at $1.75 per share.

Sessa Capital (Master), L.P. and related entities converted 17,400 shares of Series B Convertible Preferred Stock into 1,740,000 shares of SAB Biotherapeutics, Inc. common stock at $1.75 per share.

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, reported a disposition of 1,977 shares for tax withholding related to RSU vesting.

SAB Biotherapeutics' CEO and Executive Chairman, Samuel J. Reich, was granted 4.8 million stock options with an exercise price of $2.17, vesting over four years.

SAB Biotherapeutics' Chief Financial Officer, Lucy To, was granted 1.2 million stock options with an exercise price of $2.17, contingent on shareholder approval.

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, was granted 2.4 million stock options with an exercise price of $2.17, subject to shareholder approval.

SAB Biotherapeutics' Chief Operating Officer, Christoph Bausch, was granted 600,000 stock options with a $2.17 exercise price, vesting over four years.

SAB Biotherapeutics' President and Director, Eddie Joe Sullivan, was granted 3 million stock options with an exercise price of $2.17, vesting over four years.

Sessa Capital (Master), L.P. and its affiliated entities have acquired Series B Convertible Preferred Stock and accompanying warrants in SAB Biotherapeutics, Inc. for approximately $40 million, signaling a significant investment and potential future ownership stake.

An entity affiliated with SAB Biotherapeutics director Andrew Moin has acquired nearly $40 million in convertible preferred stock and warrants, signaling a significant capital infusion for the company.

Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, reports the withholding of 1,179 common stock shares to cover tax obligations related to vesting restricted stock units.

Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc., reported a transaction involving the withholding of common stock to cover tax obligations related to vested restricted stock units.

Director Helen K. Ellias receives stock option grants as part of her board membership compensation.

Lucy To, CFO of SAB Biotherapeutics, acquired options to purchase 125,000 shares of common stock on August 12, 2024.